Kelly Schats

Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression

Christophe Van Berckelaer, Charlotte Rypens, Peter A. van Dam et al. · Breast Cancer Research · 2019 · 77 citations · Full text

Medicine, Immunology, Oncology +17

A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases

Yanina Jansen, Vibeke Krüse, Jurgen Corthals et al. · Cancer Immunology Immunotherapy · 2020 · 72 citations · Full text

Medicine, Immunology, Oncology +17

Validated programmed cell death ligand 1 immunohistochemistry assays (E1L3N and <scp>SP</scp>142) reveal similar immune cell staining patterns in melanoma when using the same sensitive detection system

Kelly Schats, Emily A. Van Vré, Stefanie De Schepper et al. · Histopathology · 2016 · 39 citations · Full text

Medicine, Oncology, Pathology +17

A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab

Gil Awada, Yanina Jansen, Julia Katharina Schwarze et al. · Cancers · 2021 · 36 citations · Full text

Medicine, Clinical Sciences, Oncology +17

Phase I clinical trial of decitabine (5-aza-2'-deoxycytidine) administered by hepatic arterial infusion in patients with unresectable liver-predominant metastases

Yanina Jansen, Gontran Verset, Kelly Schats et al. · ESMO Open · 2019 · 35 citations · Full text

Medicine, Oncology, Pharmacology +14